Pharmacokinetic study of mycophenolic acid in Iranian kidney transplant patients
-
Kheirollah Gholami
,
Mohammadreza Rouini
,
Niayesh Mohebbi
,
Iman Karimzadeh
,
Mehdi Ahadi-barzoki
,
Mahboob Lessan-pezeshki
,
Saeed Rezaee
Abstract
Background: The purpose of this study was to characterize the pharmacokinetic parameters of mycophenolic acid (MPA) in Iranian kidney transplant patients.
Methods: Plasma MPA concentration of mycophenolate mofetile (MMF) 1 gram two times a day was measured in 21 Iranian kidney transplant recipients receiving treatment. Patients who entered the study had been transplanted for more than 3 months and their drug level was supposed to be at steady state. MMF concentration was measured with High- Performance Liquid Chromatography (HPLC).
Results: The plasma MPA concentration-time curve was characterized by an early sharp peak at about 1 hour postdose. The mean Area Under Curve (AUC), Cmax and Tmax were 47.0±18.3 µg.h/ml, 18.6±8.5 µg/ml and 1.0±0.5 hours respectively.
Conclusion: The plasma MPA concentration-time curve pattern of Iranian patients was similar and consistent with previously reported profiles in other populations taking the same dose.
Hariharan S, Johnson CP, Bresnahan BA, Taranato SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med. 2000; 342: 605-12.
European Mycophenolate Mofetile Cooperative Study Group. Mycophenolate mofetile in renal transplantation: 3-year results from the placebo-controlled trial. Transplantation. 1999; 68: 391-6.
Ojo AO, Meier-Kriesche HU, Hanson JA, Kaplan B. Mycophenolate mofetile reduces late renal allograft loss independent of acute rejection. Transplantation. 2000; 69: 2405-9.
Weir MR, Anderson L, Fink JC, Gabregiorgish K, Schweitzer EJ, Hoehn- Saric E, et al. A novel approach to the treatment of chronic allograft nephropathy. Transplantation. 1997; 64: 1706-10.
David-Neto E, Araujo LM, Lemos FC, David DS, Mazzucchi E, Nahas WC, et al. Introduction of mycophenolic mofetile and cyclosporin reduction in children with chronic treatment nephropathy. Pediatr Transplant. 2001; 5: 302-9.
Lemos FBC, Ianhez LE, Sabbaga E, David-Neto E. Is the improvement of renal function in chronic allograft nephropathy, after MMF introduction, related to cyclosporine reduction? Transplantation. 1999; 67: S86.
Ferraris JR, Tambutti ML, Redal MA, Bustos D, Ramirez JA, Prigoshin N. Conversion from azathioprine to mycophenolate mofetile in pediatric renal transplant recipients with chronic rejection. Transplantation. 2000; 70: 297- 301.
Pastore A, Russo A L, Piemonte F, Mannucci L, Federici G. Rapid determination of mycophenolic acid in plasma by reversed-phase high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2002; 776(2):251-4.
Morii M, Ueno K, Ogawa A, Kato R, Yoshimura H, Wada K, et al. Impairment of mycophenolate mofetile absorption by iron ion. Clin Pharmacol Ther. 2000; 68:613-6.
Yeung S, Tong KL, Tsang WK, Tang HL, Fung KS, Chan HWH, et al. Determination of mycophenolate area under the curve by limited sampling strategy. Transplant Proc. 2001; 33: 1052-3.
David-Neto E, Araujo LMP, Sumita NM, Mendes ME, Castro MCR, Alves CF, et al . Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. Pediatr Nephrol. 2003;18: 266-72.
Cho EK, Han DJ, Kim SC, Burckart GJ, Venkataramanan R, Oh JM. Pharmacokinetic study of mycophenolic acid in Korean kidney transplant patients. J Clin Pharmacol. 2004; 44: 743-50.
Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetile. Clin Pharmacokinet. 1998; 34: 429-55.
Cantin B, Giannetti N, Parekh H, Panchal SN, Kwok BW-K, Najem R, et al. Mycophenolic acid concentrations in long-term heart transplant patients: relationship with calcineurin antagonists and acute rejection. Clin Transplant. 2002; 16:196-201.
Dubrey SW, Holt DW, Banner N. Measurement of mycophenolate mofetile plasma levels after heart transplantation and a potential side effect of high levels. Ther Drug Monit. 1999; 21: 325-6.
Sanquer S, Breil M, Baron C, Dahmane D, Astier A, Lang P. Trough blood concentration in long-term treatment with mycophenolate mofetile. Lancet. 1998; 351: 1557.
Oellerich M, Shipkova M, Schütz E, Wieland E, Weber L, Tönshoff B, et al. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patient after renal transplantation: Implication for therapeutic drug minitoring. Ther Drug Monit. 2000; 22: 20-26.
Weber LT, Shipkova M, Armstrong VW, Wagner N, Schütz E, Mehls O, et al. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German study group on mycophenolate mofetile therapy. J Am Soc Nephrol. 2002; 13: 759-68.
Guellec CL, Bourgoin H, Büchler M, Meur YL, Lebranchu Y, Marquet P, et al. Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentration in stable renal transplant patients. Clin Pharmacokinet. 2004; 43: 253-66.
Van Gelder T, Hilbrands LB, Vanrenterghem Y, Weimar W, de Fijter JW, Squifflet JP, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetile for the prevention of acute rejection after kidney transplantation. Transplantation. 1999; 68: 261-66.
Shaw LM, Holt DW, Oellerich M, Meiser B, van Gelder T. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundable discussion. Ther Drug Monit. 2001; 23: 305-15.
Cattaneo D, Gaspari F, Ferrari S, Stucchi N, Del Priore L, Perico N, et al. Pharmacokinetics help optimizing mycophenolate mofetile dosing in kidney transplant patients. Clin Transplant. 2001; 15:402-9.
Mourad M, Wallemacq P, Konig J, de Frahan EH, Eddor DC, de Meyer M, et al. Therapeutic monitoring of mycophenolate mofetile in organ transplant recipients: is it necessary? Clin Pharmacokinet. 2002; 41: 319.
Cox V, Ensom M.. Mycophenolate mofetile for solid organ transplantation: does the evidence support the need for clinical pharmacokinetic monitoring? Ther Drug Monit. 2003; 25: 137-157.
Johnson AG, Rigby RJ, Taylor PJ, Jones CE, Allen J, Franzem K, et al. The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients. Clin Pharmacol Ther. 1999: 66: 492-500.
Weber LT, Lamersdorf T, Shipkova M, Niedmann PD, Wiesel M, Zimmerchackl LB, et al. Area under the plasma concentration-time curve for total, but not free, mycophenolic acid increase in the stable phase after renal transplantation: a longitudinal study in pediatric patients. Ther Drug Monit. 1999; 21: 498-506.
Brunet M, Martorell J, Oppenheimer J, Vilardell J, Millán O, Carrillo M, et al. Pharmacokinetics and pharmacodynamics of mycophenolic acid in stable renal transplant recipients treated with low doses of mycophenolate mofetile. Transpl Int. 2000; 13 [suppl 1]: S301-S305.
Shaw LM, Nawrocki A, Korecka M, Solari S, Kang J. Using established immunosuppressant therapy effectively: lessons from the measurement of mycophenolic acid plasma concentrations. Ther Drug Monit. 2004; 26: 347-51.
Shaw LM, Kaplan B, DeNofrio D, Korecka M, Brayman KL. Pharmacokinetics and concentration-control investigation of mycophenolic acid in adults after transplantation. Ther Drug Monit. 2000; 22: 14-19.
Guellec CL, Büchler M, Giraudeau B, Meur YL, Gakoue JE, Lebranchu Y, et al. Simultaneous estimation of cyclosporin and mycophenolic acid areas under the curve in stable renal transplant patients using a limited sampling strategy. Eur J Clin Pharnacol. 2001; 57: 805-11.
Filler G. Abbreviated mycophenolic acid AUC from C0, C1, C2, and C4 is preferable in children after renal transplantation on mycophenolate mofetile and tacrolimus therapy. Transpl Int. 2004; 17:120-5.
Willis C, Taylor PJ, Salm P, Tett SE, Pillans P. Evaluation of limited sampling strategies for estimation of 12-hour mycophenolic acid area under the plasma concentration-time curve in adult renal transplant patients. Ther Drug Monit. 2000; 22: 549-54.
Pisupati J, Jain A, Burckart G, Hamad I, Zuckerman S, Fung J, et al. Intraindividual and Interindividual Variations in the Pharmacokinetics of Mycophenolic Acid in Liver Transplant Patients. J Clin Pharmacol. 2005; 45:34-41.
Girard H, Court MH, Bernard O, Fortier LC, Villeneuve L, Hao Q, et al. Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics. 2004; 14: 501-15.
Smak Gregoor P IH, de Sévaux R GL, Hene RJ, Hesse CJ, Hilbrands LB, Vos P, et al. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation. 1999; 68: 1603-6.
Kuriata-Kordek M, Boratynska M, Falkiewicz K, Porazko T, Urbaniak J, Wozniak M, et al. The influence of calcineurin inhibitors on mycophenolic acid pharmacokinetics. Transplant Proc. 2003; 35: 2369-71.
Nanni G, Pisanti F, Navarra P, Boccalini F, Citterio F, Giustacchini P, et al. Lack of correlation between serum levels of mycophenolate mofetile and kidney transplant outcome in tacrolimus-based immunosuppression
Transplant Proc. 2002; 34: 2085-6.
Kuriata-Kordek M, Boratynska M, Klinger M, Wozniak M, Urbaniak J, Szyber P, et al. The efficacy of mycophenolate mofetile treatment in the prevention of acute renal rejection is related to levels of mycophenolic acid. Transplant Proc. 2002; 34: 2985-7.
Meiser BM, Groetzner J, Kaczmarek I, Landwehr P, Müller M, Jung S, et al. Tacrolimus or cyclosporine: which is the better partner for mycophenoate mofetile in heart transplant recipients? Transplantation. 2004; 78: 591-8.
Shaw LM, Korecka M, Shreeram A, Grossman R, Bayer L, Innes C, et al. Mycophenolic acid area under the curve values in African American and Caucasian renal transplant patients are comparable. J Clin Pharmacol. 2000; 40: 624-33.
Engelbertink R, Gregoor S, Hesse C, IJzermans J, Weimar W, van Gelder T. High mycophenolic acid area under-the-curve values in renal transplant recipients on long-term mycophenolate mofetile treatment. Transplant Proc. 2002; 34: 2983-4.
| Files | ||
| Issue | Vol 1, No 1 (Winter 2013) | |
| Section | Original Article(s) | |
| Keywords | ||
| Mycophenolate mofetil Mycophenolic acid Pharmacokinetics Area Under Curve Kidney transplantation | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
